

Footnotes by J.L.

I have been asked to indicate the "acceptable boundaries of control." The essential requirement is the integrity of our internal research program (DENDRAL). At the present level of operation this cannot be dissected from the overall program for SCAROX. Therefore I have indicated a line of authority whereby the P.T. would be responsible for implementing the policies enunciated by NCAIM, within the contractual understandings of mutual objectives that underlie this proposal.

The ~~A1M~~ program may well grow to the degree that other arrangements should be considered. At some scale - a point I would estimate to be ~~at a low level~~ ^{in the zone between \$1 million and} \$2 million or more per year for A1M - either the P.T. or NCAIM should have the option of deciding to propose a reorganization that might sever these responsibilities and establish new directions for the A1M sector. As every augmentation of A1M will be subject to the policy direction of NCAIM, this body will have ample latitude for monitoring the growth and direction of A1M.

DENDRAL

The direction of the ~~SCAROX~~ project will follow the lines of other research programs. The P.T. may apply to NCAIM for augmented access to SCAROX, in the same fashion as other investigators. It may also apply to NIH and other agencies for other funding. The

initial allocation of the SWER resources has, however, been formally defended in the present proposal, and assurance of its continuity is a precondition for the assumption of the heavy responsibility entailed in this proposal. DENDRAL will, of course, be subject to periodic review in the usual cycle of grant renewals.

I do not view the user-selection prerogatives of NCAIM as a restraint, but rather as an inevitable mechanism for quality control. Given, as this proposal suggests, a fair hearing mechanism in which we have a contributory (but not decisive) role, I have no qualms about the selection of a group of high quality with whom we can enthusiastically cooperate.